DaVita (DVA)
Health Care · healthcare facilities / dialysis services · NYSE
DaVita is a specialized healthcare provider focused on delivering life-sustaining dialysis and integrated kidney care services to patients with chronic kidney failure.
What DaVita does
DaVita Inc. is a leading provider of dialysis services in the United States, primarily treating patients with end-stage renal disease (ESRD) and chronic kidney disease (CKD). The company operates a vast network of outpatient dialysis centers and provides related laboratory and pharmacy services to support kidney care patients.
Themes: kidney care, chronic disease management, dialysis services
Fundamentals
- Price$177.02 as of 2026-10-08 close
- Market cap$11.3B as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return+38.4% 2025-10-08 close $127.89 → 2026-10-08 close $177.02
- P/E14.50 as of 2026-10-08
- Net margin+5.5% FY2025, SEC XBRL
- Debt / equity77.99 as of 2026-09-03
- Revenue growth (YoY)+6.5% as of 2026-09-03
- Revenue CAGR (3y)+5.5% SEC XBRL
- Beta0.34 as of 2026-09-03
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How DVA compares in its sector
- price-to-earnings ratiobottom 25% 185 covered Health Care peers, as of 2026-10-08
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
DVA is not currently in any published Top 10 list. Its scores are below.
Top 10 score
54.3 #504 of 1,379 scored · #59 of 151 in Health Care
Valuation 87th (price to earnings 14.5 (within its sector)) and profitability 60th (operating margin 15%); weakest is financial health (25th, debt to equity 78, free cash flow margin 9.6%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How DaVita looks technically
DaVita (DVA) is trading 3.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 143 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive). It made a new 20-day low about 11 trading days ago. It is 28.5% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 3.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +3.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $184.68 | $184.68 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $170.47 | $170.47 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 173.95. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 143 trading days ago — a "golden cross", a bullish long-term signal | 143 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend) | 18.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30) | 43.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($173.95 to $186.23) — its "stochastic" reading is 25 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 25.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $247.49 | $247.49 |
|---|---|---|
| From the 52-week high | it is 28.5% below its 52-week high (its highest price of the past year) | -28.5% |
| Above the 52-week low | it is 75.3% above its 52-week low (its lowest price of the past year) | +75.3% |
| Below the 52-week high | it is 28.5% below its highest point of the past year | 28.5% |
| Since a 20-day breakout | it made a new 20-day low about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day low about 34 trading days ago | 34 sessions |
| All-time high | its highest closing price on record is $247.49 (set on 2026-08-03) | $247.49 |
| Given back of the 52-week move | over the past year its closes ranged ($103.87 to $240.96), and it has given back around half of its rise from last year’s low — 47% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $151.85 to $156.24. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 46.6% |
| From the all-time high | it is 28.5% below its all-time high | -28.5% |
| Nearest price level | it is trading 0.7% below a resistance level at $178.19 — a price it turned at three times since 2025-01-31, most recently on 2026-08-07. Since 2024-10-08 it has 11 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.7% |
| All-time low | its lowest closing price on record is $20.48 (set on 2008-11-21) | $20.48 |
| Above the all-time low | it is 764.4% above its all-time low | +764.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 49th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $4.94 between its high and its low — about 2.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $4.94 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $170.55 and $191.55 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $170.55 – $181.05 – $191.55 |
| Typical daily range (% of price) | its price moves about 2.8% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.8% |
| Stretch from the 200-day average | it is trading 1.3 daily ranges above its 200-day average price (3.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.89× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
|---|---|---|
| Since a bearish engulfing | 1 session ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 1 session ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.1% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.1% |
|---|---|---|
| Open gap | it gapped 10.0% below the previous close 45 sessions ago and has not traded back through the level it left behind at 227.99 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -10.0% |
| Gap filled | a 2.5% gap down opened on 2026-08-26 has been "filled" 30 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 30 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 2.7 percentage points (the stock lost 1.7% while the market gained 1.0%) | -2.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 27.1 percentage points (the stock lost 23.3% while the market gained 3.8%) | -27.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 0.5 percentage points (the stock gained 17.9% while the market gained 17.5%) | +0.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 23.4 percentage points (the stock gained 38.4% while the market gained 15.0%) | +23.4% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 8.4% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 9.2% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -8.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 4% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $169.81 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | +4.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% below the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is under water. That average is $184.55 — a volume-weighted average of daily closes over 47 sessions, not a true tick-by-tick VWAP. | -4.1% |
Double bottom, bullish — forming · entry $193.86 · 33 sessions in
Price levels it has turned at before
DVA last closed at $177.02 on 2026-10-08. Since 2024-10-08 it has turned at 11 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $178.19 | Resistance | 0.7% above the last close | turned there three times · 2025-01-31 to 2026-08-07 |
| $169.69 | Support | 4.1% below the last close | turned there four times · 2024-10-16 to 2026-08-24 |
| $156.72 | Support | 11.5% below the last close | turned there six times · 2024-12-27 to 2026-04-23 |
| $153.19 | Support | 13.5% below the last close | turned there four times · 2024-11-19 to 2026-02-12 |
| $202.57 | Resistance | 14.4% above the last close | turned there twice · 2026-05-12 to 2026-05-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $173.95.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 1 trading day, since 2026-10-08.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · Under water since its last earnings report (below the anchored VWAP) · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.38 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$219.86 range $165.00 – $270.00; median $220.00
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DVA
- Consensus EPS estimate$3.57 next reporting period, as of 2026-10-08
- Estimate change, 30 days-$0.0031 (-0.1%) from $3.58, on 2026-09-03, 35-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant reliance on government reimbursement programs like Medicare and Medicaid.","Exposure to potential legislative or regulatory changes affecting the healthcare industry and dialysis reimbursement rates.","High levels of indebtedness and related debt service obligations."]
What changed in the latest 10-Q
AI-assisted comparison of DVA's 10-Q filed 2026-08-04 against the prior one filed 2026-05-05.
Management's Discussion & Analysis (MD&A)
- Added:
- In the newer filing (2026-08-04), the first paragraph of forward-looking statements removes the specific reference to 'the One Big Beautiful Bill Act (OBBBA)' that was present in the older filing (2026-05-05), now referencing only 'federal government policy changes or shutdowns'.
- In the newer filing (2026-08-04), the bullet on third-party vendor risks adds the word 'transition' after 'disruption' and adds the phrase ', which may, among other things, increase our costs or expenses' at the end.
- In the newer filing (2026-08-04), the final bullet on privacy or security laws ends with 'or any security br' where the older filing (2026-05-05) ends with 'or any security breach by us or a third part'.
- Removed:
- In the older filing (2026-05-05), the first paragraph of forward-looking statements included the phrase 'the impact of the One Big Beautiful Bill Act (OBBBA) and federal government policy changes or shutdowns'.
- In the older filing (2026-05-05), the bullet on third-party vendor risks read 'a closure, reduction or other disruption in the services or products provided to us' without the word 'transition' or the trailing cost/expense clause.
- Reworded:
- Changed 'the impact of the One Big Beautiful Bill Act (OBBBA) and federal government policy changes or shutdowns' (older filing, 2026-05-05) to 'the impact of federal government policy changes or shutdowns' (newer filing, 2026-08-04).
- Changed 'a closure, reduction or other disruption in the services or products provided to us by such suppliers, service providers and third party vendors;' (older filing, 2026-05-05) to 'a closure, reduction, disruption or transition in the services or products provided to us by such suppliers, service providers and third party vendors, which may, among other things, increase our costs or expenses;' (newer filing, 2026-08-04).
- Notes:
- The provided excerpts are truncated; the newer filing text ends mid-sentence at 'or any security br' and the older filing text ends mid-sentence at 'or any security breach by us or a third part'. Changes beyond the truncation point cannot be assessed.
- Page numbers differ between filings (newer: 21, older: 18), but this is a formatting difference, not a substantive text change.
Risk Factors
- Added:
- Newer filing (2026-08-04) includes a new exhibit 10.1: Ninth Amendment to Credit Agreement dated June 8, 2026, noted as filed on June 8, 2026 as an exhibit to a Form 8-K.
- Newer filing (2026-08-04) changes the exhibit description numbering and page references, including the certification dates to August 4, 2026.
- Newer filing (2026-08-04) updates the share repurchase table to cover the second quarter of 2026 (April-June) with new per-month repurchase data.
- Removed:
- Older filing (2026-05-05) included table and description of a Rule 10b5-1 trading arrangement for Kathleen A. Waters, Chief Legal and Public Affairs Officer, adopted March 16, 2026; this is absent in the newer filing (2026-08-04).
- Older filing (2026-05-05) included exhibit 10.1 described as "DaVita Inc. Amended and Restated Non-Employee Director Compensation Policy"; this exhibit is absent in the newer filing (2026-08-04).
- Reworded:
- Newer filing (2026-08-04) states the repurchase authorization available amount as approximately $1,373 million as of July 31, 2026; older filing (2026-05-05) stated approximately $1,456 million as of May 5, 2026.
- Newer filing (2026-08-04) states no director or officer adopted, modified or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the quarter ended June 30, 2026; older filing (2026-05-05) stated the same for the quarter ended March 31, 2026, but with the exception described in a table for Kathleen A. Waters.
- Newer filing (2026-08-04) refers to the second quarter of 2026 for share repurchases; older filing (2026-05-05) referred to the first quarter of 2026.
- Newer filing (2026-08-04) certification dates are August 4, 2026; older filing (2026-05-05) certification dates are May 5, 2026.
- Newer filing (2026-08-04) signature date is August 4, 2026; older filing (2026-05-05) signature date is May 5, 2026.
- Newer filing (2026-08-04) quarterly repurchase totals are 2,238 shares at average price $154.95; older filing (2026-05-05) totals were 3,005 shares at average price $133.70.
- Notes:
- This comparison is limited to the provided text which includes Item 2 and subsequent sections alongside Item 1A; the actual risk factor section text itself includes only the statement of no material changes in both filings.
- Differences were identified across the full included text block, not only the Risk Factors wording.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-05. The 4 days since 2026-10-05 have not been checked yet.
- Last 90 days · read to 2026-10-050 buys · 1 sell ($37M) — 1 selling insider
- Last 180 days · read to 2026-10-050 buys · 11 sells ($254M) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-31. Based on Form 4 filings read through 2026-10-05; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about DVA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 3 matched disclosures for DVA from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
7 institutional 13F filers reported holding DVA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 7
- Reported shares held 33,703,442
- Reported value $7,498,341,900
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 5 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about DVA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
DVA had 4,298,025 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
DVA had 6.74% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.75 days to cover at the same settlement.
- Reported short interest (shares) 4,298,025
- Short interest (% of shares outstanding) 6.74%
- Prior settlement (shares) 4,675,982
- Reported change -8.08%
- Days to cover (reported) 6.75
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Fresenius Medical Care (FMS)
- Baxter International (BAX)
- U.S. Renal Care
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare DVA vs…
DaVita is found in…
Frequently asked questions
What does DaVita (DVA) do?
DaVita Inc. is a leading provider of dialysis services in the United States, primarily treating patients with end-stage renal disease (ESRD) and chronic kidney disease (CKD). The company operates a vast network of outpatient dialysis centers and provides related laboratory and pharmacy services to support kidney care patients.
What sector is DaVita (DVA) in?
DaVita (DVA) is classified in the Health Care sector. Its industry is healthcare facilities / dialysis services. It trades on NYSE.
Who are DaVita's (DVA) competitors?
Notable peers of DaVita (DVA) include Fresenius Medical Care, Baxter International and U.S. Renal Care. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in DVA?
Yes — we hold 3 matched STOCK Act disclosures for DVA from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is DaVita (DVA) overbought or oversold right now?
DaVita (DVA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 43, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DVA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.